Renapril

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Renapril

What is Renapril?

Renapril is a medication belonging to the class of drugs known as angiotensin-converting enzyme (ACE) inhibitors. It is primarily used in the management of cardiovascular conditions, specifically focusing on the regulation of blood pressure and the reduction of strain on the heart.

Mechanism of Action

The active therapeutic process of Renapril involves the inhibition of the ACE enzyme. Under normal physiological conditions, this enzyme converts angiotensin I into angiotensin II, a potent chemical that causes blood vessels to tighten and narrow. By blocking this conversion, Renapril helps blood vessels remain more relaxed and dilated. This action lowers peripheral vascular resistance, allowing blood to flow more easily throughout the body.

Therapeutic Use

Renapril is typically utilized in the following clinical contexts:

  • Hypertension: It is used to lower high blood pressure, which helps prevent long-term damage to the arteries and vital organs such as the kidneys and brain.
  • Heart Failure: It may be used to manage chronic heart failure by improving the heart's pumping efficiency and reducing the workload required to circulate blood.
  • Left Ventricular Dysfunction: It is sometimes employed following specific cardiac events to help maintain the structural integrity and function of the heart's main pumping chamber.

By helping to manage these conditions, Renapril serves as a foundational component in long-term cardiovascular care strategies.

Regulatory References

  1. essential medicine
  2. National Library of Medicine

What side effects are possible with Renapril?

The safety profile of Renapril, whose active ingredient is Enalapril maleate, is organized by regulatory authorities according to the frequency and body system affected. These classifications reflect how government regulatory documents communicate the medicine’s established safety profile.

Frequency-Classified Adverse Reactions

The most frequently reported adverse effects are categorized as Very Common (occurring in ge 1/10 patients) or Common (occurring in ge 1/100 to <1/10 patients).

Classification Examples of Documented Reactions
Very Common Cough, Dizziness, Blurred vision, general lack of strength (Asthenia).
Common Headache, Hypotension (low blood pressure), Syncope, Diarrhoea, Fatigue, Rash, Hyperkalaemia (high potassium), and increased serum creatinine (a kidney function marker).
Rare Hepatic failure, serious blood disorders (e.g., Agranulocytosis), and severe skin reactions (e.g., Stevens-Johnson syndrome).

Serious Adverse Reactions and Safety Constraints

Official labeling defines several serious health events and restrictions on use. A critical concern is Angioedema, a potentially life-threatening swelling of the face, tongue, and throat, which may occur at any time during treatment. Cardiovascular risks such as Myocardial Infarction or Cerebrovascular Accident have been reported, sometimes secondary to excessive drops in blood pressure in vulnerable patients.

Population-Specific Safety Considerations

Pregnancy: The medicine carries a formal regulatory warning against use during the second and third trimesters due to the risk of fetal injury and death (Fetal Toxicity). Renal Impairment: Patients with pre-existing kidney issues or who are volume-depleted are noted to be at increased risk of Acute Renal Failure and severe drops in blood pressure. The risk of Angioedema has been reported to be substantially increased in Black patients.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Renapril

Overdose of Renapril (Enalapril maleate) is characterized by severe physiological manifestations, requiring immediate emergency intervention as outlined in regulatory documentation.


Documented Manifestations and Severe Outcomes

Classification Manifestation/Outcome
Cardiovascular Effects Profound hypotension (severe blood pressure drop), circulatory shock, bradycardia, and tachycardia are the primary documented signs

. | | Neurological Effects | Overdose may escalate to central nervous system effects, including stupor, convulsions, and loss of consciousness. | | Electrolyte Imbalance | Hyperkalemia (elevated serum potassium) and acute renal failure are among the documented severe physiological findings. |


Official Emergency Actions

The most prominent regulatory instruction is to seek immediate medical attention for any suspected overdose. Emergency medical care is required when these severe symptoms are present.

Regulatory sources state that no specific antidote is known for Enalapril maleate overdose. Management is symptomatic and supportive, often including the intravenous infusion of volume expanders like normal saline to manage severe hypotension. Hospital monitoring of blood pressure, serum electrolytes, and creatinine is required to assess the extent of the overdose and the patient's condition.

Therapeutic Uses of Renapril

What Renapril treats: main uses and benefits

Renapril is commonly used in situations involving certain distressing symptoms and may be part of symptomatic management applied across domains where additional symptomatic support is needed to address symptoms associated with elevated blood pressure and chronic heart strain. The medicine is commonly used to help with treating Hypertension, managing Symptomatic Heart Failure, and addressing Asymptomatic Left Ventricular Dysfunction.

In clinical settings that involve chronic symptom patterns, Renapril is relevant for easing symptoms linked to organ-specific functional stress. This support assists with maintaining functional stability when symptoms interfere with routine activities. The use of this medicine may assist with managing groups of symptoms that appear suddenly or fluctuate, such as symptoms related to systemic imbalance and physical fatigue. It provides supportive relief when symptoms interfere with routine activities, contributing to improved comfort during periods of heightened symptoms.

Quick Fact: Support for Symptoms of Systemic Imbalance
Is relevant for easing symptoms related to systemic imbalance, such as edema (swelling).

Eligibility and Restrictions for Use

Renapril (enalapril) is an Angiotensin-Converting Enzyme (ACE) inhibitor typically prescribed to treat high blood pressure (hypertension) and congestive heart failure. It may also be used to manage asymptomatic left ventricular dysfunction.

Who Can Use Renapril?

  • Adults with hypertension, heart failure, or asymptomatic left ventricular dysfunction.
  • Children (generally ge 1 month old) for the treatment of hypertension, with dosage adjusted based on body weight. Use in children with heart failure or severe kidney issues is generally not recommended.

Who Cannot Use Renapril?

Renapril is contraindicated and should not be used in the following circumstances, as it can cause serious harm:

Condition/Situation Reason for Contraindication
Pregnancy (especially second and third trimesters) High risk of fetal injury or death (renal damage, skull defects). Must be discontinued immediately if pregnancy is detected.
History of Angioedema Increased risk of recurrence, which can be life-threatening (swelling of face, tongue, throat).
Allergy Known hypersensitivity to enalapril or any other ACE inhibitor (e.g., lisinopril, ramipril).
Concomitant use with Aliskiren Contraindicated in patients with diabetes due to increased risk of hyperkalemia and renal impairment.
Concomitant use with Sacubitril/Valsartan (Entresto) Must not be taken within 36 hours before or after to avoid increased risk of angioedema.

Caution is advised for patients with existing kidney or liver disease, severe heart problems (like aortic stenosis), or those on a low-salt diet, as dosage adjustments or close monitoring may be necessary.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Renapril, whose active component is Enalapril maleate, has several formally documented interaction patterns based on government regulatory guidance. These restrictions define when and how certain other medicinal products, supplements, or substances may be co-administered.


Prohibited or Restricted Combinations

Co-administration with a Neprilysin Inhibitor (e.g., sacubitril/valsartan) is strictly contraindicated due to the significantly increased risk of angioedema. When switching between these therapies, a 36-hour waiting period is mandatory. The use of Renapril with the Renin Inhibitor Aliskiren is also contraindicated in patients with documented Diabetes Mellitus or with Renal Impairment (GFR < 60 mL/min).


Pharmacodynamic and Exposure Interactions

Co-administration with Potassium-sparing Diuretics, Potassium Supplements, or Potassium-containing salt substitutes creates an additive effect that increases the documented risk of hyperkalemia (elevated serum potassium). Combining Renapril with Lithium can lead to a reversible increase in serum lithium concentrations because of altered clearance. This requires specific regulatory instructions for monitoring serum levels.

Interaction with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, increases the official risk of deterioration of renal function. This risk is specified as higher in the elderly and those with existing compromised renal function. The product's absorption is not influenced by food, but alcohol may enhance hypotensive effects.

Mechanism of Action

Renapril, an ethyl ester pro-drug, is hydrolyzed by hepatic carboxylesterase 1 (CES1) into its active metabolite, enalaprilat, which acts as a competitive inhibitor of the angiotensin-converting enzyme (ACE).

This enzymatic inhibition prevents the cleavage of angiotensin I to form the potent vasoconstrictor, angiotensin II, thereby directly suppressing the renin-angiotensin-aldosterone system (RAAS). The reduction of circulating angiotensin II diminishes its binding to AT1 receptors on vascular smooth muscle, leading to a molecular cascade that results in vasodilation and a subsequent decrease in systemic vascular resistance. Intracellularly, reduced angiotensin II signaling lessens its stimulus for the secretion of aldosterone from the adrenal cortex. This results in decreased renal reabsorption of sodium ions and water in the distal tubules. Additionally, ACE inhibition impedes the enzymatic degradation of bradykinin, a vasodilator peptide, which further contributes to system-level arteriolar and venous dilation and modulation of circulatory fluid volume.

Dosage and Administration Information

How to Use Renapril

This section outlines the administration principles for Renapril (Enalapril maleate).

Administration Principles and Dosage Schedules

Renapril is primarily administered through the Oral route, available as tablets in multiple strengths or as a reconstituted solution. The active metabolite, Enalaprilat, has an Intravenous (IV) form for use in controlled clinical settings.

Administration is independent of meals, meaning the dose can be taken with or without food. Standard adult dosing schedules vary based on the specific condition being addressed:

  • Hypertension (HTN): Typically begins with a low initial dose of 5 mg once daily. Maintenance dosing is usually in the range of 10 mg to 40 mg per day.
  • Heart Failure (HF) and Asymptomatic Left Ventricular Dysfunction (LVD): Treatment starts at a reduced dose, often 2.5 mg once or twice daily, requiring a titration (gradual dose increase) phase over several weeks to reach a target maintenance level.

Special Procedural Instructions

Administration follows specific conditions for certain patient populations:

  • Renal Impairment: For patients with reduced kidney function (creatinine clearance le 30 mL/ min), the initial dose is reduced to 2.5 mg daily.
  • Pediatric Use: Dosing for children older than one month is based on weight (0.08 mg/ kg once daily), not to exceed 5 mg.
  • Diuretic Use: Diuretic therapy may need to be temporarily stopped (discontinued for 2 to 3 days) before initiating Renapril, or the starting dose must be lowered.

If a dose is missed, the standard procedure is to omit the missed dose and resume the regular schedule with the next dose; doses should not be doubled to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Renapril (Enalapril Maleate)


Evidence for Use in High Blood Pressure (Hypertension)

Research exploring Renapril for high blood pressure is supported by numerous large-scale Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies have primarily focused on adult populations, with additional data collected on specific subgroups, including children. Researchers carefully monitored measurable changes in both systolic and diastolic blood pressure (BP) over defined intervals as a key study outcome.

Findings describe measured changes in blood pressure in the observed populations. Additionally, long-term studies have tracked the occurrence of major cardiovascular events, such as stroke or heart attack, over several years as an outcome measurement. These findings describe group patterns related to these endpoints.

However, certain research limitations have been noted in the evidence landscape for hypertension. For instance, data for use in children younger than age six remains limited. Furthermore, some analyses reported limited or non-linear dose-response patterns for certain measured outcomes, and comparative evidence against certain newer drug types may be lacking.

Evidence for Use in Symptomatic Heart Failure

The evidence for Renapril in symptomatic heart failure is based on large-scale, long-term, placebo-controlled trials that tracked patients with a confirmed reduction in the heart's pumping ability (reduced ejection fraction). These studies, such as the CONSENSUS and SOLVD-Treatment trials, monitored hard clinical outcomes, including all-cause mortality and the frequency of hospitalization for worsening heart failure.

Research reports patterns related to the incidence of mortality observed in the groups receiving the medicine compared to control groups over observation periods lasting several months to a few years. Studies also reported patterns related to the frequency of hospitalization required due to heart failure symptoms in the observed groups. These findings describe group patterns related to these measured endpoints when compared to control groups. Researchers also monitored changes in the NYHA functional class, which is a metric used to describe physical function and the severity of symptoms in heart failure patients.

What remains uncertain is the applicability of these findings to all heart failure patient groups. Since early pivotal trials often included a run-in period to identify patients who could tolerate the medication, the results apply only to the populations studied and may not fully reflect outcomes in individuals who might have difficulty tolerating the treatment initially. Additionally, evidence concerning the effects on patients with heart failure with preserved ejection fraction (HFpEF), a different type of heart failure, appears limited or inconsistent.

Evidence for Preventing Symptom Onset in Left Ventricular Dysfunction

Dedicated prevention trials, such as the SOLVD-Prevention trial, was studied for use in individuals who showed evidence of left ventricular dysfunction (reduced LVEF) but did not yet have overt clinical heart failure symptoms. This research aimed to track the incidence of progression to symptomatic heart failure over an average follow-up duration of several years.

The prevention trials reported patterns related to the rate of new symptomatic heart failure diagnosis in the intervention group compared to the placebo group during the observation period. Studies also monitored rates of hospitalization for heart failure-related causes, with analyses reporting patterns of difference in the frequency of hospitalization between the groups. While findings for the combined endpoint of death or heart failure were reported, the effect on all-cause mortality alone was noted as a numerical difference that was not always statistically certain during the pre-defined study period.

A key limitation is that the robust evidence for this use is heavily reliant on a single large, defining trial and its subsequent extended follow-up studies, suggesting less independent replication across multiple trials. Furthermore, study results reflect the specific, asymptomatic conditions under which they were conducted and research does not determine whether an individual who is currently asymptomatic will respond similarly.

Long-Term Studies and Extended Follow-Up

The research base includes extended observational follow-up data on patients who participated in the original heart failure trials. Some of these analyses have tracked patient status for a decade or more, extending well beyond the original randomized, double-blind phase. These long-term studies contribute to the broader evidence landscape by monitoring survival patterns over the course of many years.

These studies provide context on what has been observed so far regarding the patterns seen in short-term trials over longer periods. For example, substudies measured changes in the size and shape of the heart's ventricles, with findings describing how these measurements evolved over time. However, long-term effects are not fully established through continuous, randomized observation, as the extended data often comes from observational settings after the blinding was removed.

Evidence in Specific Patient Groups

Renapril was evaluated in studies involving several specific patient groups. For the treatment of high blood pressure, research has explored its use in children and adolescents (typically aged 6 to 16) in studies that included populations with varying body weights. However, as noted, data are still insufficient for the youngest age groups.

Studies also included subgroups of older adults across the different indications. Researchers closely monitored relevant physiological strain or stress markers in older adults, who were also included in studies across the different indications. Additionally, evidence exists from substudies of patients who had co-existing kidney conditions (like chronic kidney disease) alongside symptomatic heart failure, where research examined the relationship between Renapril and clinical outcomes, with findings describing patterns related to the incidence of mortality and hospitalization in these groups.

What is Still Uncertain About Renapril Research

Despite the established evidence base from landmark trials, certain areas of research still carry limited information.

  • Data for certain groups remain insufficient, particularly for patients such as children under the age of six.
  • The certainty remains low for outcomes related to heart failure with a preserved ejection fraction (HFpEF), where the study data are often mixed and further research is ongoing.
  • Comparative evidence is lacking for some endpoints when Renapril is compared against the newest classes of cardiovascular medications.
  • Follow-up durations were limited in some of the smaller dose-comparison studies. Thus, the evidence highlights what is known—and what is still uncertain—about very long-term outcomes and how the drug interacts with the full range of modern therapies.

Key Studies & References

  1. WHO Model List of Essential Medicines (Enalapril entry)
  2. MedlinePlus: Enalapril (Pharmacological Class and Mechanism Information)

Frequently Asked Questions (FAQ)

Common questions about Renapril (FAQ)


Q: If I miss a dose of Renapril, what should I do?

If you miss a dose of Renapril, official instructions advise that you should omit the missed dose entirely and simply resume your regular schedule with the next planned dose. Regulatory instructions state that doses should not be doubled to compensate.


Q: Why do some people take Renapril in the morning and others at night?

Official product information states that the medicine's administration is independent of meals, meaning it can be taken with or without food. The decision on timing (once or twice daily) depends on the specific condition being treated, such as heart failure, as determined by the treating professional.


Q: What happens if I stop taking Renapril suddenly?

Stopping treatment abruptly, especially for conditions like heart failure, can lead to a documented worsening of symptoms. All discontinuation of therapy is typically managed under the supervision of a healthcare professional.


Q: Can I get Renapril over the counter?

Renapril is classified by regulatory authorities as a systemic prescription medicine, meaning it is not typically available without a prescription.


Q: What should I do if my side effects feel severe?

If you experience signs of a serious reaction, such as angioedema (severe swelling of the face, tongue, and throat), official documents state that seeking emergency medical attention is necessary. For any other severe or concerning symptoms, you should contact a healthcare professional right away.


Q: When should I contact a healthcare professional about side effects from Renapril?

A healthcare professional should be contacted if you experience symptoms of a serious reaction, such as the swelling associated with angioedema. You should also contact them if any adverse reaction becomes particularly bothersome or persistent and is affecting your well-being.


Q: How should Renapril be stored?

Official regulatory information mandates that tablets must be stored at controlled room temperature (20 C to 25 C). They should be kept in a tightly closed container, protected from moisture, and stored out of the sight and reach of children.


Q: How long does it usually take for Renapril to start working?

Following an oral dose, the peak blood pressure-lowering effect is generally observed within 4 to 6 hours, according to clinical pharmacology documents. However, achieving the full, intended therapeutic benefit may take several weeks of consistent use.


Q: Does Renapril cause weight gain?

Weight gain is not listed among the commonly reported adverse reactions in the official frequency-classified safety tables provided by regulatory authorities.


Q: Can Renapril affect my ability to drive or operate machinery?

Because side effects such as dizziness and fatigue may occur, regulatory documents advise caution regarding driving or operating complex machinery until the medicine's effects on the individual are known.


Q: Is it normal to feel dizzy when first starting Renapril?

Dizziness is classified as a Very Common adverse reaction, meaning it is reported in at least 1 out of 10 patients. This occurrence is often associated with the initial drop in blood pressure caused by the medication.


Q: Can Renapril be used to treat things other than high blood pressure?

Yes, according to approved product labeling, Renapril is indicated for treating hypertension (high blood pressure), symptomatic heart failure, and asymptomatic left ventricular dysfunction (a specific heart condition).


Q: Is Renapril safe for older adults?

Official information notes specific caution for older adults, particularly those with existing kidney issues. They are noted to have an increased risk of renal (kidney) deterioration when used with certain pain relievers like NSAIDs, requiring careful management as outlined in official procedural guidance.


Q: What are the most common reasons someone might be switched from Renapril to a different drug?

High-frequency side effects such as a persistent cough, or severe reactions such as angioedema (swelling), are among the documented reasons that may prompt a change in medication, as recorded in safety information.


Q: How often should I have blood tests while on Renapril?

Regulatory documents require laboratory monitoring of two specific markers: serum potassium levels and renal function (measured by serum creatinine). These tests must be performed at periodic intervals throughout treatment.


Q: Does Renapril affect kidney function over time?

The medicine can cause documented increases in serum creatinine, a marker of kidney function. Official warnings also note that certain vulnerable patients carry a risk of acute renal failure. These potential effects are monitored through periodic blood tests.


Q: Are headaches a frequent side effect of Renapril?

Headache is classified as a Common adverse reaction, meaning it is reported in 1 to 10 out of 100 patients. This places it in the category of frequently observed side effects.


Q: What should I know about taking Renapril if I have diabetes?

The use of Renapril with the Renin Inhibitor medicine Aliskiren is officially contraindicated (forbidden) for diabetic patients. This restriction is due to a heightened risk of hyperkalemia (high potassium) and renal impairment.


Q: Why is Renapril prescribed for heart failure?

Renapril is prescribed for heart failure because it functions as an ACE inhibitor, which blocks an enzyme that normally constricts blood vessels. This action leads to the dilation of blood vessels and a reduction in fluid retention, which lessens the overall workload on the heart.


Q: What research supports the use of Renapril for its main purpose?

The use of this medicine is supported by established evidence from large-scale Randomized Controlled Trials (RCTs), such as the SOLVD and CONSENSUS trials. These studies documented patterns related to cardiovascular events and mortality over defined observation periods.


Q: Can Renapril cause fatigue or low energy?

Yes, the official safety documentation lists both Fatigue as a Common adverse reaction and a general lack of strength, known as Asthenia, as a Very Common reaction. These effects are often noted during the initial phase of treatment.


Q: Is there a maximum dose of Renapril?

For the treatment of hypertension, the maximum recommended maintenance dose, as specified in regulatory documents, is 40 mg per day. Doses for other conditions, such as heart failure, may differ and are subject to specific titration schedules.


Q: What happens if a child accidentally takes Renapril?

An overdose of Renapril can cause severe hypotension (dangerously low blood pressure). Official instructions state that such an event may require emergency supportive treatment and continuous monitoring of vital signs.


Q: Does Renapril interact with birth control pills?

Official regulatory labeling does not contain a documented formal drug-drug interaction between Enalapril and hormonal contraceptives. No specific warning or dose adjustment is formally required based on current product information.


Q: Are there different strengths (dosages) of Renapril tablets?

Yes, Renapril is available as tablets in multiple strengths for oral use. These typically include 2.5 mg, 5 mg, 10 mg, and 20 mg tablets, allowing for flexible administration.


Q: What if Renapril doesn't seem to be lowering my blood pressure?

The medicine is often started at a low dose and is increased gradually over several weeks—a process called a titration phase. This gradual adjustment is part of the established procedure to determine the appropriate maintenance level.


Q: Does Renapril affect cholesterol levels?

Changes in cholesterol or other lipid (fat) parameters are not listed among the commonly reported adverse reactions in the official frequency-classified safety tables provided by regulatory authorities.


Q: Can men experience sexual side effects from Renapril?

Yes, impotence (inability to maintain an erection) is listed as an Uncommon adverse reaction in the official frequency-classified safety tables, meaning it is observed in less than 1 out of 100 patients.


Q: Does Renapril have different effects on different races or ethnic groups?

Yes, official safety warnings specifically note that the risk of the serious side effect Angioedema (swelling) is documented as substantially increased in Black patients compared to non-Black patients.


Q: How is the dose of Renapril usually determined?

Dosing is determined based on the specific condition being addressed (such as hypertension versus heart failure). Management often accounts for individual factors such as renal (kidney) function and concurrent use of diuretics (water pills).


Q: Is there a generic version of Renapril available?

Yes, the active ingredient in Renapril, which is Enalapril maleate, is widely available in a generic version, as listed in authoritative sources like the NIH DailyMed.


How should Renapril be stored and disposed of?

How to Store and Dispose of Renapril (Enalapril Maleate)

Renapril must be stored according to regulatory requirements to ensure its stability. All forms of the medicine must be stored out of the sight and reach of children and must not be frozen.

Storage Conditions

Formulation Required Temperature / Condition
Tablets Store at Controlled Room Temperature (20 C to 25 C) in a tightly closed container, protected from moisture.
Oral Solution May be refrigerated (2 C to 8 C) until its expiration date, OR stored at room temperature (20 C to 25 C) for a maximum of 60 days.

Disposal

If the oral solution is stored at room temperature for over 60 days, the unused portion must be discarded. Unused or expired medication should generally be mixed with an undesirable substance, placed in a sealed bag, and disposed of in the household trash if a drug take-back program is unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Renapril found in:

A-Z Index: